A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

ClinicalTrials.gov ID: NCT02443155

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02443155. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted globally. The aim of this trial is to assess the clinical proof-of-principle of NNC0114-0006 and liraglutide on preservation of beta-cell function in adult subjects with newly diagnosed type 1 diabetes mellitus.

Study identification

NCT ID: NCT02443155
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Novo Nordisk A/S; Industry
Enrollment: 308 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 45 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 10, 2015 (Actual)
Primary completion: Aug 31, 2018 (Actual)
Completion: Feb 27, 2019 (Actual)
Last update posted: Apr 9, 2021

2015 – 2019

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Novo Nordisk Investigational Site	La Jolla	California	92037	—
Novo Nordisk Investigational Site	Northridge	California	91325	—
Novo Nordisk Investigational Site	Aurora	Colorado	80045	—
Novo Nordisk Investigational Site	Miami	Florida	33136	—
Novo Nordisk Investigational Site	Orlando	Florida	32804	—
Novo Nordisk Investigational Site	Atlanta	Georgia	30318	—
Novo Nordisk Investigational Site	Lexington	Kentucky	40503	—
Novo Nordisk Investigational Site	Las Vegas	Nevada	89128	—
Novo Nordisk Investigational Site	Teaneck	New Jersey	07666	—
Novo Nordisk Investigational Site	Chapel Hill	North Carolina	27517	—
Novo Nordisk Investigational Site	Nashville	Tennessee	37203	—
Novo Nordisk Investigational Site	Houston	Texas	77079	—
Novo Nordisk Investigational Site	Mesquite	Texas	75149	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02443155, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 9, 2021 · Synced Nov 12, 2026